What is the appropriate treatment for acute gout in a 70-year-old male with involvement of the left great toe?

Treatment of Acute Gout in a 70-Year-Old Male

For this 70-year-old man with acute gout affecting his left great toe, initiate treatment with oral corticosteroids (prednisolone 35 mg daily for 5 days) as first-line therapy, as they are equally effective to NSAIDs and colchicine but have a superior safety profile in elderly patients with likely comorbidities. 1

First-Line Treatment Options

The 2020 ACR and 2017 ACP guidelines both strongly recommend three equally effective first-line agents for acute gout 2, 1:

• Corticosteroids (oral, intramuscular, or intraarticular)
• NSAIDs (any NSAID, not just indomethacin)
• Colchicine (low-dose: 1.2 mg followed by 0.6 mg one hour later)

Why Corticosteroids Are Preferred in This 70-Year-Old Patient

Corticosteroids should be your first choice in elderly patients because:

• High-quality evidence shows they are as effective as NSAIDs for pain reduction 3, 4
• They have significantly fewer gastrointestinal adverse effects (lower risk of indigestion, nausea, and vomiting) 3
• They avoid the renal toxicity concerns of NSAIDs, which is critical in elderly patients who commonly have age-related renal impairment 5
• Prednisolone 35 mg daily for 5 days is the evidence-based regimen 1

Alternative Options and Their Limitations

NSAIDs: While effective, they carry substantial risks in a 70-year-old:

• Contraindicated or high-risk in patients with renal disease, heart failure, or cirrhosis 1
• Increased risk of gastrointestinal bleeding, perforation, and ulcers 1
• No NSAID is superior to another; indomethacin has no advantage despite traditional use 1

Colchicine: Effective but with caveats:

• Use only low-dose regimen (1.2 mg then 0.6 mg one hour later) 1
• More expensive than corticosteroids 1
• Contraindicated in renal or hepatic impairment with concurrent P450 3A4 or P-glycoprotein inhibitors 1
• Common gastrointestinal side effects (diarrhea, nausea, vomiting) 1

Critical Timing Consideration

Start treatment immediately upon symptom recognition. The ACR guidelines emphasize early intervention and recommend a "medication-in-pocket" strategy for patients who can identify early flare signs 2. Efficacy of all agents is highest when administered early after symptom onset.

Adjunctive Therapy

Add topical ice to the affected joint as an adjuvant treatment alongside your chosen anti-inflammatory agent 2.

What NOT to Do for This Acute Attack

Do not initiate urate-lowering therapy (allopurinol, febuxostat) during the acute flare. This is a common pitfall. The ACP strongly recommends against starting long-term urate-lowering therapy during or immediately after a first gout attack 1. Urate-lowering therapy should only be considered after the acute attack resolves and only if the patient has recurrent attacks (≥2 per year), tophi, chronic kidney disease, or urolithiasis 1.

If Oral Medications Cannot Be Taken

Use parenteral glucocorticoids (intramuscular or intravenous) over IL-1 inhibitors or ACTH if the patient cannot take oral medications 2. This is strongly recommended based on accessibility and cost considerations.

Second-Line Options for Treatment Failure

If the initial agent fails or is contraindicated:

• Switch to one of the other first-line agents (corticosteroids, NSAIDs, or colchicine)
• Consider IL-1 inhibitors (canakinumab) only if all conventional therapies are ineffective, poorly tolerated, or contraindicated 2
• Moderate-quality evidence shows canakinumab 150 mg is more effective than intramuscular triamcinolone 40 mg 4, but cost and access are significant barriers

Key Comorbidity Considerations in the Elderly

At age 70, carefully assess for 5:

• Renal function: Creatinine clearance affects both NSAID and colchicine safety
• Cardiovascular disease: Common in gout patients; NSAIDs increase cardiovascular risk
• Diabetes: Corticosteroids may transiently elevate glucose
• Concomitant medications: Many drugs increase serum urate and interact with gout treatments

The safety profile of short-course corticosteroids (5 days) makes them the most appropriate choice for most elderly patients with acute gout, balancing efficacy with minimal risk. 1, 3